# Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)

> **NCT00653744** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1700 (estimated)

## Conditions studied

- Hypercholesterolemia
- Dyslipidaemia

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00653744
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 1700 (ESTIMATED)
- **Last updated:** 2009-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00653744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00653744, "Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00653744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*